MicroRNA-200b and -301 are associated with gemcitabine response as biomarkers in pancreatic carcinoma cells
- 7 January 2019
- journal article
- research article
- Published by Spandidos Publications in International Journal of Oncology
- Vol. 54 (3) , 991-1000
Abstract
Chemotherapy resistance (congenital or acquired) is one of the principal challenges for the treatment of pancreatic carcinoma. Recent evidence has demonstrated that epithelial to mesenchymal transition (EMT) is associated with chemoresistance in pancreatic carcinoma cells. However, the molecular mechanism underlying the development of chemoresistance remains unknown, and limited therapeutic options are available. Therefore, to anticipate individual chemosensitivity or acquired chemoresistance for patients with pancreatic carcinoma, predictive biomarkers are urgently required. Extensive evidence suggests that microRNAs (miRNAs) serve a crucial role in regulating EMT. The aim of this study was to examine the potential role of miRNA (miR)-200b and miR-301 in predicting the chemo-responses to treatment for pancreatic carcinoma. The present results demonstrate that miR-200b expression predicted chemo-sensitivity and may have potential as a biomarker. In six different pancreatic carcinoma cell lines (Capan-1, Capan-2, Panc-1, MIAPaCa-2, BxPC-3 and PL45 cells), the expression of miR-200b correlated positively with chemosensitivity. Moreover, the enhanced expression of miR-200b increased chemosensitivity and induced mesenchymal to epithelial transition. Conversely, miR-301 modulated gemcitabine resistance and induced EMT through the downregulation of cadherin 1 expression. In addition, gemcitabine-resistant cells (Capan-2 and Panc-1) exhibited upregulated miR-301 expression and downregulated gemcitabine-induced apoptosis. In summary, these two miRNAs may serve roles as biomarkers in pancreatic carcinoma, miR-200b expression may predict chemosensitivity, and elevated miR-301 expression may have potential applications in the prediction of acquired gemcitabine resistance.Keywords
This publication has 46 references indexed in Scilit:
- MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive reviewEMBO Molecular Medicine, 2012
- A miR-200b/200c/429-Binding Site Polymorphism in the 3′ Untranslated Region of the AP-2α Gene Is Associated with Cisplatin ResistancePLOS ONE, 2011
- RETRACTED ARTICLE: EGFR and MET receptor tyrosine kinase–altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancersNature Medicine, 2011
- Gemcitabine Plusnab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II TrialJournal of Clinical Oncology, 2011
- miR‐301a as an NF‐κB activator in pancreatic cancer cellsThe EMBO Journal, 2010
- Targeting miRNAs involved in cancer stem cell and EMT regulation: An emerging concept in overcoming drug resistanceDrug Resistance Updates, 2010
- Preoperative/Neoadjuvant Therapy in Pancreatic Cancer: A Systematic Review and Meta-analysis of Response and Resection PercentagesPLOS Medicine, 2010
- Up-regulation of miR-200 and let-7 by Natural Agents Leads to the Reversal of Epithelial-to-Mesenchymal Transition in Gemcitabine-Resistant Pancreatic Cancer CellsCancer Research, 2009
- Expression profiling identifies microRNA signature in pancreatic cancerInternational Journal of Cancer, 2006
- Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT MethodMethods, 2001